Elan partner Wyeth predicts success

ELAN’s up and down year has turned positive with US drug giant, Wyeth — which partners Elan on its in-development Alzheimer’s treatments — saying drugs they are working on “may have a higher likelihood of succeeding than anybody’s”.

Last week, Elan’s multiple sclerosis drug, Tysabri came in for knocking. After it recently emerged the drug could cause liver damage, the European Medicines Agency requested that a warning be included on the product’s labels.